A groundbreaking examine means that mind cancer may lastly be cured with the assistance of artificial intelligence.

Scientists have developed a strong device that decodes the DNA of tumours whereas sufferers are present process surgical procedure.

This game-changing breakthrough opens the door to tailor-made remedies for one of the vital deadly types of the illness.

Dr Kun-Hsing Yu, a number one researcher from Harvard Medical School, mentioned: "Right now, even state-of-the-art clinical practice cannot profile tumours molecularly during surgery.

"Our device overcomes this problem by extracting thus-far untapped biomedical alerts from frozen pathology slides."

The breakthrough could significantly boost the survival rates of individuals battling the deadliest brain cancer known as glioblastoma. 

Currently, the vital information undergoes laboratory testing, which often takes weeks to complete.

However, knowing a tumour's molecular type enables neurosurgeons to make immediate decisions, such as whether to administer drugs directly to the brain during surgery.

Dr Yu said: "The capacity to find out intraoperative molecular prognosis in actual time, throughout surgical procedure, can propel the event of real-time precision oncology."

The standard approach used now involves freezing brain tissue for microscopic examination. However, this alters cell appearance, impacting clinical evaluation accuracy. Additionally, even with advanced scanners, the human eye struggles to detect subtle genomic variations on a slide.

The promising AI device, called CHARM (Cryosection Histopathology Assessment and Review Machine) holds the potential to address these challenges.

Once validated through clinical testing in real-world settings, the team hopes that the device will obtain approval from the US Food and Drug Administration for hospital use.

In the UK, there are approximately 2,500 diagnosed cases each year. Tragically, the majority of patients do not survive beyond two years, with only a small number living beyond five years. This statistic has shown no improvement for decades.

Scientists have already designed AI models to profile bowel, lung and breast. Glioblastomas have remained particularly challenging due to their molecular complexity.

Dr Yu said: "Just like human clinicians who should interact in ongoing training and coaching, AI instruments should sustain with the most recent data to stay at peak efficiency."

CHARM is described within the journal Med.